+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Aradigm Corporation - logo

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. The company’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

From
From
From
From
From
From
Anthrax (Infectious Disease) - Drugs in Development, 2021 - Product Thumbnail Image

Anthrax (Infectious Disease) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Plague (Infectious Disease) - Drugs in Development, 2021 - Product Thumbnail Image

Plague (Infectious Disease) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
From
Type II DNA topoisomerase inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Type II DNA topoisomerase inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 85 Pages
  • Global
From
Controlled Release Drug Delivery Global Market Report 2024 - Product Thumbnail Image

Controlled Release Drug Delivery Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Smoking Cessation - Pipeline Insight, 2024 - Product Thumbnail Image

Smoking Cessation - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Needle-Free Devices: Technologies and Global Markets - Product Thumbnail Image

Needle-Free Devices: Technologies and Global Markets

  • Report
  • March 2019
  • 170 Pages
  • Global
From
Loading Indicator